Literature DB >> 20488188

Monocytic fibroblast precursors mediate fibrosis in angiotensin-II-induced cardiac hypertrophy.

Sandra B Haudek1, Jizhong Cheng, Jie Du, Yanlin Wang, Jesus Hermosillo-Rodriguez, JoAnn Trial, George E Taffet, Mark L Entman.   

Abstract

Angiotensin-II (Ang-II) is an autacoid generated as part of the pathophysiology of cardiac hypertrophy and failure. In addition to its role in cardiac and smooth muscle contraction and salt retention, it was shown to play a major role in the cardiac interstitial inflammatory response and fibrosis accompanying cardiac failure. In this study, we examined a model of Ang-II infusion to clarify the early cellular mechanisms linking interstitial fibrosis with the onset of the tissue inflammatory response. Continuous infusion of Ang-II resulted in increased deposition of collagen in the heart. Ang-II infusion also resulted in the appearance of distinctive small, spindle-shaped, bone marrow-derived CD34(+)/CD45(+) fibroblasts that expressed collagen type I and the cardiac fibroblast marker DDR2 while structural fibroblasts were CD34(-)/CD45(-). Genetic deletion of monocyte chemoattractant protein (MCP)-1 (MCP-1-KO mice) prevented the Ang-II-induced cardiac fibrosis and the appearance of CD34(+)/CD45(+) fibroblasts. Real-time PCR in Ang-II-treated hearts revealed a striking induction of types I and III collagen, TGF-beta1, and TNF mRNA expression; this was obviated in Ang-II-infused MCP-1-KO hearts. In both wild-type and MCP-1-KO mice, Ang-II infusion resulted in cardiac hypertrophy, increased systolic function and hypertension which were not significantly different between the WT and MCP-1-KO mice over the 6-week course of infusion. In conclusion, the development of Ang-II-induced non-adaptive fibrosis in the heart required induction of MCP-1, which modulated the uptake and differentiation of a CD34(+)/CD45(+) fibroblast precursor population. In contrast to the inflammatory and fibrotic response, the hemodynamic response to Ang-II was not affected by MCP-1 in the first 6weeks. Copyright 2010 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20488188      PMCID: PMC2917526          DOI: 10.1016/j.yjmcc.2010.05.005

Source DB:  PubMed          Journal:  J Mol Cell Cardiol        ISSN: 0022-2828            Impact factor:   5.000


  44 in total

1.  Bone marrow-derived fibroblast precursors mediate ischemic cardiomyopathy in mice.

Authors:  Sandra B Haudek; Ying Xia; Peter Huebener; John M Lee; Signe Carlson; Jeff R Crawford; Darrell Pilling; Richard H Gomer; JoAnn Trial; Nikolaos G Frangogiannis; Mark L Entman
Journal:  Proc Natl Acad Sci U S A       Date:  2006-11-17       Impact factor: 11.205

Review 2.  Role of the renin-angiotensin system in vascular diseases: expanding the field.

Authors:  M Ruiz-Ortega; O Lorenzo; M Rupérez; V Esteban; Y Suzuki; S Mezzano; J J Plaza; J Egido
Journal:  Hypertension       Date:  2001-12-01       Impact factor: 10.190

3.  Fibrocytes from burn patients regulate the activities of fibroblasts.

Authors:  Jian Fei Wang; Haiyan Jiao; Tara L Stewart; Heather A Shankowsky; Paul G Scott; Edward E Tredget
Journal:  Wound Repair Regen       Date:  2007 Jan-Feb       Impact factor: 3.617

Review 4.  Protective effect of the inhibition of the renin-angiotensin system on aging.

Authors:  Nidia Basso; Nora Paglia; Inés Stella; Elena M V de Cavanagh; León Ferder; María del Rosario Lores Arnaiz; Felipe Inserra
Journal:  Regul Pept       Date:  2005-06-30

Review 5.  Immune activation in chronic heart failure.

Authors:  Guillermo Torre-Amione
Journal:  Am J Cardiol       Date:  2005-06-06       Impact factor: 2.778

Review 6.  Chemokines in myocardial ischemia.

Authors:  Nikolaos G Frangogiannis; Mark L Entman
Journal:  Trends Cardiovasc Med       Date:  2005-07       Impact factor: 6.677

Review 7.  The role of TGF-beta signaling in myocardial infarction and cardiac remodeling.

Authors:  Marcin Bujak; Nikolaos G Frangogiannis
Journal:  Cardiovasc Res       Date:  2006-10-07       Impact factor: 10.787

8.  Adrenomedullin inhibits angiotensin II-induced oxidative stress and gene expression in rat endothelial cells.

Authors:  Takanobu Yoshimoto; Naoki Gochou; Nozomi Fukai; Toru Sugiyama; Masayoshi Shichiri; Yukio Hirata
Journal:  Hypertens Res       Date:  2005-02       Impact factor: 3.872

Review 9.  Chemokines in the ischemic myocardium: from inflammation to fibrosis.

Authors:  N G Frangogiannis
Journal:  Inflamm Res       Date:  2004-11       Impact factor: 4.575

10.  Critical role of monocyte chemoattractant protein-1/CC chemokine ligand 2 in the pathogenesis of ischemic cardiomyopathy.

Authors:  Nikolaos G Frangogiannis; Oliver Dewald; Ying Xia; Guofeng Ren; Sandra Haudek; Thorsten Leucker; Daniela Kraemer; George Taffet; Barrett J Rollins; Mark L Entman
Journal:  Circulation       Date:  2007-02-06       Impact factor: 29.690

View more
  89 in total

Review 1.  Valvular heart diseases in the developing world: developmental biology takes center stage.

Authors:  Emily J Farrar; Jonathan T Butcher
Journal:  J Heart Valve Dis       Date:  2012-03

Review 2.  Cardiac fibrosis: potential therapeutic targets.

Authors:  Shuin Park; Ngoc B Nguyen; Arash Pezhouman; Reza Ardehali
Journal:  Transl Res       Date:  2019-03-09       Impact factor: 7.012

3.  Immune-inflammatory dysregulation modulates the incidence of progressive fibrosis and diastolic stiffness in the aging heart.

Authors:  Katarzyna A Cieslik; George E Taffet; Signe Carlson; Jesus Hermosillo; Joann Trial; Mark L Entman
Journal:  J Mol Cell Cardiol       Date:  2010-10-23       Impact factor: 5.000

4.  CXCR6 plays a critical role in angiotensin II-induced renal injury and fibrosis.

Authors:  Yunfeng Xia; Xiaogao Jin; Jingyin Yan; Mark L Entman; Yanlin Wang
Journal:  Arterioscler Thromb Vasc Biol       Date:  2014-05-22       Impact factor: 8.311

5.  AMP-activated protein kinase/myocardin-related transcription factor-A signaling regulates fibroblast activation and renal fibrosis.

Authors:  Yuguo Wang; Li Jia; Zhaoyong Hu; Mark L Entman; William E Mitch; Yanlin Wang
Journal:  Kidney Int       Date:  2017-07-21       Impact factor: 10.612

6.  Dissecting the role of myeloid and mesenchymal fibroblasts in age-dependent cardiac fibrosis.

Authors:  JoAnn Trial; Celia Pena Heredia; George E Taffet; Mark L Entman; Katarzyna A Cieslik
Journal:  Basic Res Cardiol       Date:  2017-05-06       Impact factor: 17.165

Review 7.  Targeting cardiac fibroblasts to treat fibrosis of the heart: focus on HDACs.

Authors:  Katherine B Schuetze; Timothy A McKinsey; Carlin S Long
Journal:  J Mol Cell Cardiol       Date:  2014-03-11       Impact factor: 5.000

Review 8.  Inflammation in nonischemic heart disease: initiation by cardiomyocyte CaMKII and NLRP3 inflammasome signaling.

Authors:  Takeshi Suetomi; Shigeki Miyamoto; Joan Heller Brown
Journal:  Am J Physiol Heart Circ Physiol       Date:  2019-08-23       Impact factor: 4.733

9.  Valproic acid regulates Ang II-induced pericyte-myofibroblast trans-differentiation via MAPK/ERK pathway.

Authors:  Yan Zhang; Feng Gao; Yuan Tang; Jinwen Xiao; Chuanchuan Li; Yu Ouyang; Yuemei Hou
Journal:  Am J Transl Res       Date:  2018-07-15       Impact factor: 4.060

10.  Unique mechanistic insights into the beneficial effects of soluble epoxide hydrolase inhibitors in the prevention of cardiac fibrosis.

Authors:  Padmini Sirish; Ning Li; Jun-Yan Liu; Kin Sing Stephen Lee; Sung Hee Hwang; Hong Qiu; Cuifen Zhao; Siu Mei Ma; Javier E López; Bruce D Hammock; Nipavan Chiamvimonvat
Journal:  Proc Natl Acad Sci U S A       Date:  2013-03-14       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.